Evidence map›Paper›PMID 39998560›Full record

ArticleZeitschrift fur Gerontologie und Geriatrie2025

[Gout : From the diagnosis to guideline-based treatment].

Vanessa Bartsch, Kathrin Standfest, Axel Hueber

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in Zeitschrift fur Gerontologie und Geriatrie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Vanessa Bartsch
Kathrin Standfest
Axel HueberAbteilung Rheumatologie, Klinikum Nürnberg, Paracelsus Medizinische Universität, Nürnberg, Deutschland. axel.hueber@klinikum-nuernberg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gout is an autoinflammatory disease triggered by chronic hyperuricemia and causes extremely painful joint inflammation. If left untreated gout can lead to irreversible joint damage and significantly impair the quality of life of affected patients. In addition to classical diagnostic methods, such as serum uric acid measurement and joint aspiration, imaging techniques, such as ultrasound and dual-energy computed tomography (CT) are becoming increasingly more important. The treatment of acute gout attacks focuses on nonsteroidal anti-inflammatory drugs (NSAID), glucocorticoids and colchicine. The long-term management involves uric acid-lowering treatment with xanthine oxidase inhibitors (e.g., allopurinol). Another key element of treatment is flare prevention during the first months of uric acid-lowering treatment to minimize the risk of further gout attacks. As gout is a chronic disease adherence to the intake of uric acid-lowering medications is crucial for long-term treatment success.

Indexed as

Anti-Inflammatory Agents, Non-SteroidalGoutGout SuppressantsGuideline AdherencePractice Guidelines as TopicAgedEvidence-Based MedicineGlucocorticoidsHumansTreatment OutcomeUric AcidAnti-Inflammatory Agents, Non-SteroidalGlucocorticoidsGout SuppressantsUric AcidAutoinflammatory diseasesGouty arthritisGouty arthropathyHyperuricemiaTophi

Identifiers

PMID39998560

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.